It has been reported that U.S. pharmacy benefit manager CVS will drop Sanofi’s insulin drugs, Lantus^® (insulin glargine injection, 100 units/ml) and Toujeo^® (insulin glargine injection, 300 units/ml) from the list of medications for which it reimburses on behalf of health insurers.  In July CVS caremark^® published a list of Formulary Drug Removals which indicates that in place of Lantus^®, CVS will reimburse for Eli Lilly’s insulin glargine injection (100 units/ml) biosimilar, Basaglar^®, and for Novo’s Levemir^® (insulin detemir injection, 100 units/ml).  Basaglar^® was approved in late 2016 and Levemir^® was approved in 2005.